sales@fnfresearch.comTel: +91 96043 17127 | USA: 1 (347) 690-0211

Search Market Research Report

Home / Category / Healthcare / Irritable Bowel Syndrome (IBS) Diagnostics

Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), And By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026

  • Publish On: Jun-2021
  • Total Pages: 175
  • Report Code: FAF-1512
  • Base Year: 2020
  • Format:

Industry Insights

[175+ Pages Report] The latest report published by facts and factors titled “irritable bowel syndrome (IBS) diagnostics market” has a global perspective on the latter coupled with the market size, volume, drivers, and restraints to name a few. We estimate that the global irritable bowel syndrome (IBS) diagnostics market will hold a value of USD 2.3 Billion by 2026 with a CAGR growth of 9.7% which was previously subjected at USD 1.2 Billion in the year 2020.

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: Overview

Irritable bowel syndrome is a disorder that targets the gastrointestinal tract causing the patients to suffer from a range of symptoms such as extreme discomfort in the stomach, diarrhea, cramping, and constipation, among others. IBS usually can occur over prolonged periods of diarrhea (gastroenteritis) which is caused by the presence of bacteria in the bowels. Early signs of IBS can range from lactose intolerance and breathe tests regarding bacterial overgrowth and can be fairly diagnosed by blood and stool sample tests. Advanced IBS can be detected by CT scans or X-rays, upper endoscopies, and colonoscopy.

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: Growth Factors

The global irritable bowel syndrome diagnostics market is heavily driven by factors governing a higher prevalence of targeted diseases coupled with increased uptake of drugs during the forecast. Additional factors include a rise in the commercialization of existing product lines spread across various regions will further propel the growth of the market. Increased approval of linzess on a global scale will open new opportunities for the market to recoup revenue and improve sales. Improved testing methods and reliable treatment measures will further drive market growth. Moreover, an advent increase in factors pertaining to increased food allergies, predominant development of gastroenteritis, sporadic movements of the colon, the irregular composition of serotonin in the colon, and a rise in celiac diseases among the aging and advanced population will further boost the demand for  IBS diagnostics over the projected forecast.

Increased awareness among consumers and manufacturers alike is expected to boost the growth of the irritable bowel syndrome (IBS) diagnostics market towards a large footprint. Collaborative efforts of global and local organizations are proving to be highly fruitful for a larger group of consumers to be made aware of IBS. An increased number of approved products from regulatory bodies across the globe open new market avenues for the IBS diagnostics market to flourish. However, lack of proper knowledge among consumers and unconfirmed diagnosis prescribed by similar practitioners is expected to constrain the growth of the market to a certain extent.

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: Segmentation

The global irritable bowel syndrome (IBS) diagnostic market can be segmented into type, product, distribution channel, and regions.

The global irritable bowel syndrome (IBS) diagnostic market can be divided into ISB-C, ISB-D, and Mixed IBS on the basis of type. The IBS-C can be further broken down into linzess/constella, amitiza, and others and the IBS-D can be broken down into xifaxan, viberzi, and others. The cholera-predominant category is expected to witness the largest market share during the advent of the forecast owing to factors pertaining to rising uptake of drugs in the form of linzess/constella and amitiza. The segment of diarrhea-predominant category is expected to witness the fastest growing CAGR during the forecast owing to launches of various products which show high promises under clinical trials. The global irritable bowel syndrome (IBS) diagnostics market can be fragmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others on the basis of product. The segment pertaining to rifaximin is expected to witness the largest market share during the forecast owing to various contributing factors such as the increasing prevalence of IBS among the geriatric population, increase in consumer awareness, effective diagnosis, and development of advanced processes. The global irritable bowel syndrome (IBS) diagnostics market can be broken down into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies on the basis of distribution channels.

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: Regional Analysis

North America is expected to witness the largest market share during the forecast period in terms of global revenue collection. The presence of key players in the region along with advancements in technology detecting IBS will propel the region to hold a dominant position in the market. Additional factors fuelling the growth of the market can be contributed to the factors such as rising patient awareness and increased consumer spending targeted toward Diagnostics testing. Europe further accounts for a significant share in the market in terms of volume and sales followed by the region of Asia-Pacific. Growing population suffering from IBS and rising incentives are a common trend observed across the significant growth of the IBS Diagnostics market across both regions.

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: competitive Players

The key participants in the global irritable bowel syndrome (IBS) diagnostics market are Allergan, Astellas Pharma, Inc., Takeda Pharmaceuticals Company Limited, AstraZeneca, Sebela Pharmaceuticals, Inc., Synergy Pharmaceuticals, Banusch Health, Synthetic Biologics, Inc., Ardelyx, Johnson & Johnson, and Novartis AG, among others.

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Type Segment Analysis

  • ISB-C    
    • Linzess/Constella
    • Amitiza
    • Others
  • ISB-D
    • Xifaxan
    • Viberzi
    • Others
  • Mixed IBS

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Product Segment Analysis

  • Rifaximin
  • Eluxadoline
  • Lubiprostone
  • Linaclotide
  • Others

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Distribution Channel Segment Analysis

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Regional Segment Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of MEA

KEY REPORT POINTERS & HIGHLIGHTS:

  • Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable
  • Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward
  • Micro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable  Segments and Sub-segments of the Market
  • Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data
  • Historical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario Analysis
  • Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications
  • Value Chain and Supply Chain Analysis along with Horizontal and Vertical Integration Scenarios
  • Manufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevant
  • Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market
  • Market Attractiveness Analysis and Key Investment Opportunity Analysis in the Market going forward
  • Technological Roadmap, Patents Analysis, Potential Substitutes, and Technical Analysis
  • The professionally substantiated market research report study is calculated, constructed, and assembled by implementing a Robust Research Methodology. The Triangular Process comprises a buoyant mix of Exhaustive Primary Research (focused interviews, questionnaires, and ad-hoc surveys) and Extended Secondary Research (paid external databases, proprietary in-house database, and publically-available validated sources), where it is finally triangulated and validated through in-house industry experts, industry leaders, and independent consultants through a tri-level quality check practice.

Table of Content

  1. Chapter 1 Executive Summary
    1. 1.1. Introduction of Irritable Bowel Syndrome (IBS) Diagnostics
    2. 1.2. Global Irritable Bowel Syndrome (IBS) Diagnostics Market, 2020 & 2026 (USD Billion)
    3. 1.3. Global Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    4. 1.4. Global Irritable Bowel Syndrome (IBS) Diagnostics Market Absolute Revenue Opportunity, 2016 – 2026 (USD Billion)
    5. 1.5. Global Irritable Bowel Syndrome (IBS) Diagnostics Market Incremental Revenue Opportunity, 2020 – 2026 (USD Billion)
  2. Chapter 2 Irritable Bowel Syndrome (IBS) Diagnostics Market – Type Analysis
    1. 2.1. Global Irritable Bowel Syndrome (IBS) Diagnostics Market – Type Overview
    2. 2.2. Global Irritable Bowel Syndrome (IBS) Diagnostics Market Share, by Type, 2020 & 2026 (USD Billion)
    3. 2.3. IBS-C
      1. 2.3.1. Global IBS-C Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    4. 2.4. IBS-D
      1. 2.4.1. Global IBS-D Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    5. 2.5. Mixed IBS
      1. 2.5.1. Global Mixed IBS Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
  3. Chapter 3 Irritable Bowel Syndrome (IBS) Diagnostics Market – Product Analysis
    1. 3.1. Global Irritable Bowel Syndrome (IBS) Diagnostics Market – Product Overview
    2. 3.2. Global Irritable Bowel Syndrome (IBS) Diagnostics Market Share, by Product, 2020 & 2026 (USD Billion)
    3. 3.3. Rifaximin
      1. 3.3.1. Global Rifaximin Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    4. 3.4. Eluxadoline
      1. 3.4.1. Global Eluxadoline Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    5. 3.5. Lubiprostone
      1. 3.5.1. Global Lubiprostone Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    6. 3.6. Linaclotide
      1. 3.6.1. Global Linaclotide Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    7. 3.7. Others
      1. 3.7.1. Global Others Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
  4. Chapter 4 Irritable Bowel Syndrome (IBS) Diagnostics Market – Distribution Channels Analysis
    1. 4.1. Global Irritable Bowel Syndrome (IBS) Diagnostics Market – Distribution Channels Overview
    2. 4.2. Global Irritable Bowel Syndrome (IBS) Diagnostics Market Share, by Distribution Channels, 2020 & 2026 (USD Billion)
    3. 4.3. Hospital Pharmacies
      1. 4.3.1. Global Hospital Pharmacies Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    4. 4.4. Drug Stores & Retail Pharmacies
      1. 4.4.1. Global Drug Stores & Retail Pharmacies Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    5. 4.5. Online Pharmacies
      1. 4.5.1. Global Online Pharmacies Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
  5. Chapter 5 Irritable Bowel Syndrome (IBS) Diagnostics Market – Regional Analysis
    1. 5.1. Global Irritable Bowel Syndrome (IBS) Diagnostics Market Regional Overview
    2. 5.2. Global Irritable Bowel Syndrome (IBS) Diagnostics Market Share, by Region, 2020 & 2026 (USD Billion)
    3. 5.3. North America
      1. 5.3.1. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
        1. 5.3.1.1. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.3.2. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026
        1. 5.3.2.1. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026 (USD Billion)
      3. 5.3.3. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026
        1. 5.3.3.1. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026 (USD Billion)
      4. 5.3.4. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026
        1. 5.3.4.1. North America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      5. 5.3.5. U.S.
        1. 5.3.5.1. U.S. Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      6. 5.3.6. Canada
        1. 5.3.6.1. Canada Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    4. 5.4. Europe
      1. 5.4.1. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
        1. 5.4.1.1. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.4.2. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026
        1. 5.4.2.1. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026 (USD Billion)
      3. 5.4.3. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026
        1. 5.4.3.1. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026 (USD Billion)
      4. 5.4.4. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026
        1. 5.4.4.1. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      5. 5.4.5. Germany
        1. 5.4.5.1. Germany Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      6. 5.4.6. France
        1. 5.4.6.1. France Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
          1. 5.4.7. U.K.
            1. 5.4.7.1. U.K. Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      7. 5.4.8. Italy
        1. 5.4.8.1. Italy Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      8. 5.4.9. Spain
        1. 5.4.9.1. Spain Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      9. 5.4.10. Rest of Europe
        1. 5.4.10.1. Rest of Europe Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    5. 5.5. Asia Pacific
      1. 5.5.1. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
        1. 5.5.1.1. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.5.2. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026
        1. 5.5.2.1. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026 (USD Billion)
      3. 5.5.3. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026
        1. 5.5.3.1. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026 (USD Billion)
      4. 5.5.4. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026
        1. 5.5.4.1. Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      5. 5.5.5. China
        1. 5.5.5.1. China Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      6. 5.5.6. Japan
        1. 5.5.6.1. Japan Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      7. 5.5.7. India
        1. 5.5.7.1. India Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      8. 5.5.8. South Korea
        1. 5.5.8.1. South Korea Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      9. 5.5.9. South-East Asia
        1. 5.5.9.1. South-East Asia Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      10. 5.5.10. Rest of Asia Pacific
        1. 5.5.10.1. Rest of Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    6. 5.6. Latin America
      1. 5.6.1. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
        1. 5.6.1.1. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.6.2. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026
        1. 5.6.2.1. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026 (USD Billion)
      3. 5.6.3. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026
        1. 5.6.3.1. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026 (USD Billion)
      4. 5.6.4. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026
        1. 5.6.4.1. Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      5. 5.6.5. Brazil
        1. 5.6.5.1. Brazil Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      6. 5.6.6. Mexico
        1. 5.6.6.1. Mexico Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      7. 5.6.7. Rest of Latin America
        1. 5.6.7.1. Rest of Latin America Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
    7. 5.7. The Middle-East and Africa
      1. 5.7.1. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
        1. 5.7.1.1. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.7.2. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026
        1. 5.7.2.1. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, by Type, 2016 – 2026 (USD Billion)
      3. 5.7.3. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026
        1. 5.7.3.1. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, by Product, 2016 – 2026 (USD Billion)
      4. 5.7.4. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026
        1. 5.7.4.1. The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      5. 5.7.5. GCC Countries
        1. 5.7.5.1. GCC Countries Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      6. 5.7.6. South Africa
        1. 5.7.6.1. South Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
      7. 5.7.7. Rest of Middle-East Africa
        1. 5.7.7.1. Rest of Middle-East Africa Irritable Bowel Syndrome (IBS) Diagnostics Market, 2016 – 2026 (USD Billion)
  6. Chapter 6 Irritable Bowel Syndrome (IBS) Diagnostics Market – Competitive Landscape
    1. 6.1. Competitor Market Share – Revenue
    2. 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 6.3. Strategic Developments
      1. 6.3.1. Acquisitions and Mergers
      2. 6.3.2. New Products
      3. 6.3.3. Research & Development Activities
  7. Chapter 7 Company Profiles
    1. 7.1. Allergan
      1. 7.1.1. Company Overview
      2. 7.1.2. Product/Service Portfolio
      3. 7.1.3. Allergan Sales, Revenue, and Gross Margin
      4. 7.1.4. Allergan Revenue and Growth Rate
      5. 7.1.5. Allergan Market Share
      6. 7.1.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    2. 7.2. Astellas Pharma Inc
      1. 7.2.1. Company Overview
      2. 7.2.2. Product/Service Portfolio
      3. 7.2.3. Astellas Pharma Inc Sales, Revenue, and Gross Margin
      4. 7.2.4. Astellas Pharma Inc Revenue and Growth Rate
      5. 7.2.5. Astellas Pharma Inc Market Share
      6. 7.2.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    3. 7.3. Takeda Pharmaceuticals Company Limited
      1. 7.3.1. Company Overview
      2. 7.3.2. Product/Service Portfolio
      3. 7.3.3. Takeda Pharmaceuticals Company Limited Sales, Revenue, and Gross Margin
      4. 7.3.4. Takeda Pharmaceuticals Company Limited Revenue and Growth Rate
      5. 7.3.5. Takeda Pharmaceuticals Company Limited Market Share
      6. 7.3.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    4. 7.4. AstraZeneca
      1. 7.4.1. Company Overview
      2. 7.4.2. Product/Service Portfolio
      3. 7.4.3. AstraZeneca Sales, Revenue, and Gross Margin
      4. 7.4.4. AstraZeneca Revenue and Growth Rate
      5. 7.4.5. AstraZeneca Market Share
      6. 7.4.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    5. 7.5. Sebela Pharmaceuticals Inc
      1. 7.5.1. Company Overview
      2. 7.5.2. Product/Service Portfolio
      3. 7.5.3. Sebela Pharmaceuticals Inc Sales, Revenue, and Gross Margin
      4. 7.5.4. Sebela Pharmaceuticals Inc Revenue and Growth Rate
      5. 7.5.5. Sebela Pharmaceuticals Inc Market Share
      6. 7.5.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    6. 7.6. Synergy Pharmaceuticals
      1. 7.6.1. Company Overview
      2. 7.6.2. Product/Service Portfolio
      3. 7.6.3. Synergy Pharmaceuticals Sales, Revenue, and Gross Margin
      4. 7.6.4. Synergy Pharmaceuticals Revenue and Growth Rate
      5. 7.6.5. Synergy Pharmaceuticals Market Share
      6. 7.6.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    7. 7.7. Banusch Health
      1. 7.7.1. Company Overview
      2. 7.7.2. Product/Service Portfolio
      3. 7.7.3. Banusch Health Sales, Revenue, and Gross Margin
      4. 7.7.4. Banusch Health Revenue and Growth Rate
      5. 7.7.5. Banusch Health Market Share
      6. 7.7.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    8. 7.8. Synthetic Biologics Inc
      1. 7.8.1. Company Overview
      2. 7.8.2. Product/Service Portfolio
      3. 7.8.3. Synthetic Biologics Inc Sales, Revenue, and Gross Margin
      4. 7.8.4. Synthetic Biologics Inc Revenue and Growth Rate
      5. 7.8.5. Synthetic Biologics Inc Market Share
      6. 7.8.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    9. 7.9. Ardelyx
      1. 7.9.1. Company Overview
      2. 7.9.2. Product/Service Portfolio
      3. 7.9.3. Ardelyx Sales, Revenue, and Gross Margin
      4. 7.9.4. Ardelyx Revenue and Growth Rate
      5. 7.9.5. Ardelyx Market Share
      6. 7.9.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    10. 7.10. Johnson & Johnson
      1. 7.10.1. Company Overview
      2. 7.10.2. Product/Service Portfolio
      3. 7.10.3. Johnson & Johnson Sales, Revenue, and Gross Margin
      4. 7.10.4. Johnson & Johnson Revenue and Growth Rate
      5. 7.10.5. Johnson & Johnson Market Share
      6. 7.10.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    11. 7.11. Novartis AG
      1. 7.11.1. Company Overview
      2. 7.11.2. Product/Service Portfolio
      3. 7.11.3. Novartis AG Sales, Revenue, and Gross Margin
      4. 7.11.4. Novartis AG Revenue and Growth Rate
      5. 7.11.5. Novartis AG Market Share
      6. 7.11.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
  8. Chapter 8 Irritable Bowel Syndrome (IBS) Diagnostics — Industry Analysis
    1. 8.1. Introduction and Taxonomy
    2. 8.2. Irritable Bowel Syndrome (IBS) Diagnostics Market – Key Trends
      1. 8.2.1. Market Drivers
      2. 8.2.2. Market Restraints
      3. 8.2.3. Market Opportunities
    3. 8.3. Value Chain Analysis
    4. 8.4. Key Mandates and Regulations
    5. 8.5. Technology Roadmap and Timeline
    6. 8.6. Irritable Bowel Syndrome (IBS) Diagnostics Market – Attractiveness Analysis
      1. 8.6.1. By Type
      2. 8.6.2. By Product
      3. 8.6.3. By Distribution Channels
      4. 8.6.4. By Region
  9. Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    1. 9.1. Irritable Bowel Syndrome (IBS) Diagnostics Industrial Chain Analysis
    2. 9.2. Downstream Buyers
    3. 9.3. Distributors/Traders List
  10. Chapter 10 Marketing Strategy Analysis
    1. 10.1. Marketing Channel
    2. 10.2. Direct Marketing
    3. 10.3. Indirect Marketing
    4. 10.4. Marketing Channel Development Trends
    5. 10.5. Economic/Political Environmental Change
  11. Chapter 11 Report Conclusion & Key Insights
    1. 11.1. Key Insights from Primary Interviews & Surveys Respondents
    2. 11.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  12. Chapter 12 Research Approach & Methodology
    1. 12.1. Report Description
    2. 12.2. Research Scope
    3. 12.3. Research Methodology
      1. 12.3.1. Secondary Research
      2. 12.3.2. Primary Research
      3. 12.3.3. Statistical Models
        1. 12.3.3.1. Company Share Analysis Model
        2. 12.3.3.2. Revenue Based Modeling
      4. 12.3.4. Research Limitations

      List of Figures

      Fig.1	Product Picture of Irritable Bowel Syndrome (IBS) Diagnostics
      Fig.2	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.3	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market Absolute Revenue Opportunity, 2016 – 2026 (USD Billion)
      Fig.4	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market Incremental Revenue Opportunity, 2020 – 2026 (USD Billion)
      Fig.5	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market Share, by Type, 2020 & 2026 (USD Billion)
      Fig.6	Global IBS-C Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.7	Global IBS-D Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.8	Global Mixed IBS Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.9	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market Share, by Product, 2020 & 2026 (USD Billion)
      Fig.10	Global Rifaximin Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.11	Global Eluxadoline Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.12	Global Lubiprostone Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.13	Global Linaclotide Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.14	Global Others Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.15	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market Share, by Distribution Channels, 2020 & 2026 (USD Billion)
      Fig.16	Global Hospital Pharmacies Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.17	Global Drug Stores & Retail Pharmacies Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.18	Global Online Pharmacies Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.19	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market Share, by Region, 2020 & 2026 (USD Billion)
      Fig.20	North America Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.21	U.S. Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.22	Canada Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.23	Europe Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.24	Germany Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.25	France Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.26	U.K. Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.27	Italy Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.28	Spain Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.29	Rest of Europe Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.30	Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.31	China Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.32	Japan Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.33	India Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.34	South  Korea Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.35	South-East Asia Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.36	Rest of Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.37	Latin America Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.38	Brazil Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.39	Mexico Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.40	Rest of Latin America Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.41	The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.42	GCC Countries Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.43	South Africa Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.44	Rest of Middle-East Africa Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2016 – 2026 (USD Billion)
      Fig.45	Competitor Market Share – Revenue
      Fig.46	Allergan Revenue and Growth Rate
      Fig.47	Allergan Market Share
      Fig.48	Astellas Pharma Inc Revenue and Growth Rate
      Fig.49	Astellas Pharma Inc Market Share
      Fig.50	Takeda Pharmaceuticals Company Limited Revenue and Growth Rate
      Fig.51	Takeda Pharmaceuticals Company Limited Market Share
      Fig.52	AstraZeneca Revenue and Growth Rate
      Fig.53	AstraZeneca Market Share
      Fig.54	Sebela Pharmaceuticals Inc Revenue and Growth Rate
      Fig.55	Sebela Pharmaceuticals Inc Market Share
      Fig.56	Synergy Pharmaceuticals Revenue and Growth Rate
      Fig.57	Synergy Pharmaceuticals Market Share
      Fig.58	Banusch Health Revenue and Growth Rate
      Fig.59	Banusch Health Market Share
      Fig.60	Synthetic Biologics Inc Revenue and Growth Rate
      Fig.61	Synthetic Biologics Inc Market Share
      Fig.62	Ardelyx Revenue and Growth Rate
      Fig.63	Ardelyx Market Share
      Fig.64	Johnson & Johnson Revenue and Growth Rate
      Fig.65	Johnson & Johnson Market Share
      Fig.66	Novartis AG Revenue and Growth Rate
      Fig.67	Novartis AG Market Share
      Fig.68	Market Dynamics
      Fig.69	Global Irritable Bowel Syndrome (IBS) Diagnostics  – Value Chain Analysis
      Fig.70	Key Mandates and Regulations
      Fig.71	Technology Roadmap and Timeline
      Fig.72	Market Attractiveness Analysis – By Type
      Fig.73	Market Attractiveness Analysis – By Product
      Fig.74	Market Attractiveness Analysis – By Distribution Channels
      Fig.75	Market Attractiveness Analysis – By Region
      Fig.76	Irritable Bowel Syndrome (IBS) Diagnostics  Industrial Chain Analysis
      Fig.77	Market Channels
      Fig.78	Marketing Channel Development Trend
      Fig.79	Growth in World Gross Product, 2008-2018
      

      List of Tables

      Table 1	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market, 2020 & 2026 (USD Billion)
      Table 2	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Type, 2016 – 2026 (USD Billion)
      Table 3	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Product, 2016 – 2026 (USD Billion)
      Table 4	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      Table 5	Global Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Region, 2016 – 2026 (USD Billion)
      Table 6	North America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Country, 2016 – 2026 (USD Billion)
      Table 7	North America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Type, 2016 – 2026 (USD Billion)
      Table 8	North America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Product, 2016 – 2026 (USD Billion)
      Table 9	North America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      Table 10 Europe Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Country, 2016 – 2026 (USD Billion)
      Table 11 Europe Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Type, 2016 – 2026 (USD Billion)
      Table 12 Europe Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Product, 2016 – 2026 (USD Billion)
      Table 13 Europe Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      Table 14 Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Country, 2016 – 2026 (USD Billion)
      Table 15 Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Type, 2016 – 2026 (USD Billion)
      Table 16 Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Product, 2016 – 2026 (USD Billion)
      Table 17 Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      Table 18 Latin America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Country, 2016 – 2026 (USD Billion)
      Table 19 Latin America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Type, 2016 – 2026 (USD Billion)
      Table 20 Latin America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Product, 2016 – 2026 (USD Billion)
      Table 21 Latin America Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      Table 22 The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Country, 2016 – 2026 (USD Billion)
      Table 23 The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Type, 2016 – 2026 (USD Billion)
      Table 24 The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Product, 2016 – 2026 (USD Billion)
      Table 25 The Middle-East and Africa Irritable Bowel Syndrome (IBS) Diagnostics  Market, by Distribution Channels, 2016 – 2026 (USD Billion)
      Table 26 Global Irritable Bowel Syndrome (IBS) Diagnostics  Market - Company Revenue Analysis, 2016 – 2020 (USD Billion)
      Table 27 Global Irritable Bowel Syndrome (IBS) Diagnostics  Market - Company Revenue Share Analysis, 2016 – 2020 (%)
      Table 28 Acquisitions and Mergers
      Table 29 Market Drivers – Impact Analysis
      Table 30 Market Restraints
      Table 31 Market Opportunities
      Table 32 Major Buyers of Irritable Bowel Syndrome (IBS) Diagnostics
      Table 33 Distributors/Traders of Irritable Bowel Syndrome (IBS) Diagnostics  by Region
      

Industry Major Market Players

  • Allergan
  • Astellas Pharma Inc.
  • Takeda Pharmaceuticals Company Limited
  • AstraZeneca
  • Sebela Pharmaceuticals Inc.
  • Synergy Pharmaceuticals
  • Banusch Health
  • Synthetic Biologics Inc.
  • Ardelyx
  • Johnson & Johnson
  • Novartis AG

Safe and Secure SSL Encrypted

Choose License Type

Inquiry For Buying

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

have a question

HAVE A QUESTION? Executive will help you find what you are looking for.


REQUEST CUSTOMIZATION

Still haven't found what you're looking for? Speak to our Custom Research Team

Learn More
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2021 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions